Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alternative therapies and cost-effectiveness analysis, is warranted.DisclosuresShah: Amgen: Research Funding; Janssen: Research Funding. Park: Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy; Shire: Consultancy; AstraZeneca: Consultancy; Pfizer: Consultancy; Novartis: Consultancy; Kite Pharma: Consultancy; Juno Therapeutics: Consultancy, Research Funding. Sauter: Juno Therapeutics: Consultancy, Research Funding; Sanofi-Genzyme: Consultancy, Research Funding; Spectrum Pharmaceuticals: Consultancy; Novartis: Consultancy; Precision Biosciences: Consultancy; Kite: Consultancy. Palomba: Pharmacyclics: Consultancy; Celgene: Consultancy. Younes: Genentech: Research Funding; BMS: Honoraria, Research Funding; Pharmacyclics: Research Funding; Abbvie: Honoraria; Merck: Honoraria; Takeda: Honorar...
Source: Blood - Category: Hematology Authors: Shah, G. L., Park, J. H., Sauter, C. S., Duck, E., Halton, E., Palomba, M. L., Batlevi, C. L., Younes, A., Geyer, M. B., Smith, E. L., Mailankody, S., Mead, E., Santomasso, B., Perales, M.-A., Sabbatini, P., Giralt, S., Brentjens, R. J., Bach, P. Tags: 902. Health Services Research-Malignant Diseases: Overuse, Costs, and Utilization of Health Services Source Type: research
More News: Actemra | Acute Leukemia | Acute Lymphoblastic Leukemia | Alternative and Complementary Therapies | AstraZeneca | Biotechnology | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Complementary Medicine | CT Scan | Databases & Libraries | Education | Electrocardiogram | Genetics | Hematology | Hodgkin's Disease | Intensive Care | Laboratory Medicine | Leukemia | Liver | Lumbar Puncture | Lymphoma | Merck | Myeloma | Non-Hodgkin's Lymphoma | PET Scan | Pfizer | Pharmaceuticals | Radiology | Statistics | Study | Toxicology | Ultrasound | Universities & Medical Training | Urology & Nephrology | X-Ray